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ABSTRACT 
This study aimed to consider consequences of multiple sclerosis for patients in Sweden 
throughout various stages of the life course. The thesis was separated into four constituent 
papers, which dealt with different aspects of the disease, its symptoms, and implications 
at different life stages. 
The first study considers life expectancy, one of the most crucial aspects concerning the 
implications of the consequences of a chronic disease. The paper found MS patients had a 
hazard ratio (HR) for mortality of 2.92 (95% confidence interval (CI) 2.86-2.99)) at any 
given age relative to a group of non-MS comparators when the entire study period from 
1968 to 2012 was analysed. When trends were considered, however, it was shown that 
the improvement to survival for MS patients had been considerable, and dropped from an 
HR of 6.52 (95% CI 5.79–7.34) when considering the earliest time period (1968 to1980), 
down to an HR of 2.08 (95% CI 1.95–2.22) for the most recent time period (2001 to 
2012). Cause specific mortality also improved over time for MS patients, with mortality 
beginning to more closely reflect mortality trends for the general population. The largest 
excess mortality for MS patients came from respiratory and infectious diseases. 
Cardiovascular disease was the leading cause of death for both the MS and non-MS 
cohorts.  
Alongside issues pertaining to life expectancy, how patients are affected by their 
symptoms is an important consideration when answering questions about consequences 
of MS. Pain has been noted as a particularly distressing symptom by MS patients, and 
previous studies have indicated it is likely MS patients experience pain to a greater degree 
than the general population. As far as we are aware, however, there have been very few 
studies making direct comparisons of pain between MS patients and non-MS comparators 
with regard to pain, perhaps due to difficulties in drawing direct comparisons. In order to 
attempt objectivity and a fair comparison across MS and non-MS subjects, the second and 
third studies utilized the prescribed drugs register (PDR) of Sweden in order to ascertain 
when prescriptions for pain relief had been collected. An excess of pain relief 
prescriptions would imply an excess of pain among MS patients. Information on pain 
type can also be extracted using this method through the anatomical therapeutic code 
(ATC) entered into the PDR. Study two was able to provide evidence supporting the 
hypothesized increased risk of pain among MS patients, and demonstrated MS patients 
had an HR of 2.52 (95% CI 2.38-2.66) for overall pain prescription. It was additionally 
shown that this increased risk of pain was primarily driven by increased likelihood of 
neuropathic pain. The HR for MS patients being prescribed these treatments relative to 
their non-MS comparators was 5.73 (95% CI 5.07-6.47). MS patients were also at 
marginally increased risk of anti-migraine preparation prescriptions, however no 
increased risk of prescriptions for the treatment of musculoskeletal pain was detected. 
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Study three followed on from study two, which considered pain relief prescription, and 
included the same definition of the outcome. However, the study aimed primarily to 
consider the effect of genotype on MS and pain phenotype. Past murine studies have 
indicated that the major histocompatibility complex (MHC) is associated with pain-like 
behavior when considering peripheral nerve injury, however the same association was not 
observed when considering injury to the central nervous system (CNS), which more 
closely mimics the nervous system injuries seen in MS patients due to demyelination. 
Past research has identified that the DQB1*0302 class II HLA genes are associated with 
neuropathic pain presentation in individuals undergoing surgery for inguinal hernia, or for 
spinal disc herniation. As far as we are aware, the role of this allele in pain presentation, 
and whether it is differential by MS status has not been previously studied. A modest 
increased risk of pain for non-MS carriers of the DQB1*0302 allele was found, with an 
odds ratio (OR) of 1.18 (95% CI 1.03-1.35), however no increased risk was identified for 
MS patients (OR 1.02, (95% CI 0.85-1.24)), mimicking the results found in murine 
studies. 
Given that the average age at diagnosis is childbearing age for women, and that the 
majority of patients are women, issues surrounding MS and pregnancy were important to 
consider when answering questions of consequences of MS. Paper four assessed whether 
exposure to interferon –beta during pregnancy influenced intrauterine growth, by 
considering its effect on birth weight, height, and head circumference. This was an 
international study comprised of data from both Sweden and Finland. The study, which 
used prescribed medication to identify pre-natal exposure, and additionally the MS 
register within Sweden, concluded that exposure to interferon-beta did not seem to be 
associated with intrauterine growth in either Sweden or Finland.  
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INTRODUCTION 
Multiple sclerosis (MS) is the leading non-traumatic cause of disability among young 
people1-4, and yet the effect it has on the lives of people living with the disease is 
incompletely described. The disease is chronic in nature, and progresses over may years, 
making it difficult to study using conventional methods such as questionnaires and 
follow-up studies, due to issues such as attrition. It can also be complicated studying 
personal experiences and outcomes of chronic diseases using subjective measures which 
require recall from patients and other study participants. 
The use of large scale register data allows for a unique opportunity in investigating the 
long term consequences of MS. Within Sweden, administrative records of health, 
mortality, and other important outcomes and exposures have been kept for several 
decades, all of which can be linked using Swedish personal identification numbers5, 
giving the opportunity to look into consequences of MS without the concerns relating to 
attrition and response bias6. Records are available for the entire population of residents 
within Sweden, allowing for matched cohort studies with follow-up times that can span 
for decades, which has the potential to elucidate suspected associations which had 
previously been limited to anecdotal evidence taken from patient and clinician 
experience, or from smaller scale studies with shorter study times. 
MS patients can be differently affected by their disease depending on their stage of life7. 
This thesis attempts to take what we considered to be important stages during the life 
course and the disease progression, and study how patients were affected using primarily 
register data.  The ability to consider 45 years of follow-up in one of our studies enabled 
us to investigate life expectancy and mortality rates overall, and by specific causes of 
death, with considerably more power and information than has been available for 
previous research into this area. Using pain prescriptions as an objective proxy for a pain 
diagnosis, we were able to study to what extent the hypothesised increased risk of pain 
for MS patients was found in our data. Genetic susceptibility to pain according to MS 
status was studied through register data, coupled with genetic information collected from 
the blood samples of MS and matched comparators. Pregnancy outcomes in the form of 
birth measurements again taken from registers allowed us to consider how infants 
exposed to MS treatment during pregnancy are affected, relative to those born to mothers 
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who decide to discontinue treatment. This removes the effect of recall bias, and allows 
for a more objective approach into how infants may be affected by treatment exposure, a 
question of primary concern to women with MS who decide to become pregnant. This 
can be particularly pertinent because many individuals are diagnosed with MS at an age 
which coincides with decisions to become a parent. Our hope is that all four studies will 
be beneficial and provide insight into the consequences of MS for patients in Sweden at 
different points in a patient’s life.  
1. BACKGROUND 
1.1. DEFINITION AND BACKGROUND OF MS 
MS is an autoimmune disease which leads to demyelination and subsequent damage to 
neurons 8-12. Myelin is a lipoprotein produced by oligodentrocyte cells, which enables 
fast, saltatory impulse propagation13. Damage to myelin has importance for the 
functioning of the CNS, and can lead to symptoms including visual impairment, muscle 
weakness, and areas of numbness, symptoms which are often present in MS patients14. 
The disease is characterised by the formation of focal demyelinated plaques in the white 
matter tissue of the central nervous system (CNS)15. In the early, usually relapsing stages 
of the disease (see section 1.3), MS is mainly characterised as a disease of the white 
matter, however in the later, progressive disease stages, cortical demyelination and injury 
due to inflammation of all white and grey matter can be observed16.  
1.2. CLINICAL DIAGNOSIS 
Diagnosing MS can be difficult, and usually relies on ruling out other possible causes of 
symptoms. In order for a diagnosis of MS to be considered accurate, there should be 
evidence of injury to the CNS from demyelination due to inflammation, often in the form 
of a lesion17. Oligocolonal bands, proteins which indicate inflammation of the CNS, can 
also point to an MS diagnosis18. The McDonald criteria, established in 2001 as a tool for 
MS diagnosis based primarily on the concept of evidence of disseminated lesions in time 
and space19 remains the gold standard, objective measurement for determining the 
presence of MS in an individual. Further revisions to the criteria have been proposed 
since its initial implementation, including simplifications to the use of imaging which 
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mean dissemination of injury to the CNS in space and time now have the potential to be 
ascertained through a single scan20, 21. 
The methods available to provide evidence for MS during the diagnostic process have 
changed over time, in particular with the development of, and improvements to, magnetic 
resonance imaging (MRI) techniques22. Prior to the development of detailed MRIs, 
examination of cerebrospinal fluid (CSF) for the purposes of ascertaining whether levels 
of immunoglobulin production were increased was one of the fundamental diagnostic 
tests for MS22. The alterations and evolution of diagnostic criteria over time can 
potentially impact the characteristics of those defined as having MS, which makes 
comparisons over time more complicated. Recent innovations in MRI technology has 
enabled earlier detection and diagnosis of the disease and earlier possibility to begin 
disease-modifying treatments is therefore possible. The impact this has had on various 
aspects of the disease course and implications for patients have historically been difficult 
to study. The consequences of living with the disease both in recent years, and prior to 
improved diagnostic techniques, is an important study area which could provide valuable 
insights into the prognosis of MS for patients, and how this may have changed over time. 
1.3 SUBTYPES OF MS 
MS can be separated into four broad categories: relapsing remitting (RR), secondary 
progressive (SP), primary progressive (PP), and progressive relapsing (PR)7. RR MS is 
the most common subtype, with approximately 85% of incident diagnoses falling into 
this category. This subtype is defined by exacerbation of symptoms followed by periods 
of remission, during which a patient may have no or reduced symptoms. For some 
patients with RR MS, SP MS eventually develops, usually after a number of years23. It is 
believed disease modifying treatments can reduce the risk of SP MS development in 
some individuals24. For patients who develop this subtype, the symptoms continue to 
worsen with reduced probability of remission between episodes of worsening symptoms. 
PP MS is a rarer form of MS, which affects approximately 10% of MS patients. This 
disease subtype is known to be more resistant to conventional MS treatments, and is 
marked by a worsening of symptoms from the onset of disease with no episodes of 
remission or relapse25. Instead, a gradual worsening of symptoms is experienced by the 
patient. The last subtype, PR MS is present in approximately 5% of MS patients, and is 
progressive from disease onset, although debate continues as to whether this subtype is 
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indeed a distinct clinical phenotype. This group of patients experience worsening of 
symptoms, with relapses followed by plateaus or phases in which symptoms worsen 
more gradually. Patients in this subgroup do not experience episodes of remission26. 
2. THE EPIDEMIOLOGY OF MS 
MS is the most frequently diagnosed demyelinating disease1, with prevalence highest in 
North America and Europe, and lowest in sub-Saharan Africa and East Asia27. The ratio 
of diagnoses of MS between females and males is approximately 3:128. The reasons 
behind the increased likelihood of receiving a diagnosis of MS for women are 
incompletely understood, however several hypotheses have been proposed including 
differences in hormone levels, and genetic differences28. The ratio appears to have 
widened in many European countries in recent decades, revealing an increase in MS 
among women but not among men29, however this trend was not confirmed using 
Swedish data, suggesting the underlying mechanisms may be complex and context 
specific30. 
MS is most commonly diagnosed between the ages of 20 and 50 years, with a mean age 
of approximately 35 years at diagnosis.  Disease course and prognosis has been shown to 
differ depending on age at diagnosis, although age and cohort effects can be difficult to 
disentangle31. RR MS is often diagnosed at a younger age relative to other MS subtypes, 
with a mean age at diagnosis of approximately 30 years compared to a mean of 40 years 
of age for both SP, and PP MS. PR MS is the least common subtype, meaning less is 
known about the characteristics of individuals affected by this MS type, however there is 
some evidence to suggest the mean age at diagnosis is approximately 35 years of age, 
falling between the mean age for RR MS and other subtypes32. 
2.1  RISK FACTORS 
The causes and risk factors of MS remain incompletely understood, although there are 
several proposed risk factors, which include genetic predisposition, pattern of exposure to 
the Epstein-Barr virus, which could be argued to comprise a portion of the hygiene 
hypothesis,  insufficient exposure to sunlight and vitamin D, obesity and smoking33.  
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2.1.1. Genetic predisposition 
Olsson et al. describe a possible ‘pathogenetic pathway’, in which genetic susceptibility 
interacts with lifestyle factors, impacting on the functioning of immunity within an 
individual33. A gene-environment interaction is suggested to be a plausible route, with 
lifestyle therefore recommended as a target for preventative measures given that lifestyle 
can be altered. Genes within the HLA complex are the strongest genetic indicators of MS 
risk34, and are responsible for products which present antigens to CD4 T lymphocytes, 
and CD8 lymphocytes. In addition, several SNPs (single nucleotide polymorphisms) on 
the human genome outside the HLA complex have also been identified as possible risk 
factors for MS35. The pathogenetic pathway hypothesis posits that these genes interact 
with lifestyle and behavioural factors, in such a way that the risk of developing MS 
among those exposed to both genetic and behavioural factors is higher than the additive 
effect of exposure to each risk factor, indicating an interactive effect33. Such lifestyle 
factors include smoking, although exposure to nicotine through oral tobacco has been 
shown to be protective against MS, obesity, and levels of vitamin D exposure. 
2.1.2. Epstein-Barr virus and vitamin D 
Exposure to Epstein-Barr virus is another commonly cited potential causal agent of MS36. 
The relationship between MS and exposure to the virus is difficult to ascertain, and 
several other infectious agents have been proposed to be associated with increased risk of 
MS development33. The evidence of an association with the Epstein-Barr virus is, 
however, particularly compelling, in part due to a consensus that the virus is significantly 
more common amongst MS patients than those without MS37, 38. The inflammatory 
process through which this pathway may function has been under discussion for many 
years, and is largely based on observations of the nature of demyelination and injury to 
the CNS observed in MS patients, along with abnormalities found in the cerebrospinal 
fluid (CSF)38. Here the potential interaction between development of MS and insufficient 
vitamin D exposure has been explored, with one hypothesis suggesting when an 
individual is exposed to vitamin D, the number of CD8+ T cells increases, which in turn 
increases the ability of the immune system to control the EBV infection. The implication 
is those with insufficient vitamin D exposure are left susceptible to the spread of the 
infection, and are less able to control the virus, and thus become more susceptible to the 
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development and subsequent diagnosis of MS39.  Whether or not the relationship between 
EBV and development of MS is causal or is an association remains to be proven. 
Coinciding with the hypothesis that vitamin D exposure may influence the development 
of MS is the concept that latitude appears to be associated with risk of MS, with 
incidence and prevalence positively associated with an increase in latitude40. This 
association is, however, not constant across countries. Furthermore, the effect of latitude 
appears to have decreased in recent years, which suggests latitude may be a confounder 
rather than a risk factor in itself40. 
2.1.3. Hygiene hypothesis and autoimmunity 
The hygiene hypothesis theorises that the growing burden in the industrialised world of 
allergic and autoimmune conditions may relate to reduced exposure to infection41. 
Through improved hygiene, antibiotic use and vaccination programmes, the human 
immune system may be altered, and become prone to respond inappropriately to harmless 
substances42, resulting in hypersensitivity. Hypersensitivity refers to the process by which 
the immune system responds to non-pathologic antigens, which can take the form of an 
immune response to allergens and result in an allergic reaction43, or a response to the 
body’s own tissue, which then results in autoimmunity44. MS is believed to primarily be a 
result of type IV hypersensitivity, which is associated with pathologic T-cells, in 
particular regarding CD4 T cell responses45. It is well established that T cells with 
specificity for myelin are involved in MS development46, however other potential 
mechanisms of hypersensitivity have also been implicated. MS has, for example, been 
linked to type II hypersensitivity involving the presence of autoantibodies47. 
Autoantibodies are produced by the immune system in response to the presence of a 
constituent of its own tissues, and can sometimes be detected in serum many years before 
symptoms manifest44. When considering specifically MS, anti-myelin basic protein 
autoantibodies have been detected in patient serum, proteins which historically were 
generally believed to be absent from the serum of non-MS individuals48. However, recent 
research has indicated that myelin-reactive autoantibodies can also be found in the serum 
of individuals without MS49, making it difficult to ascertain the pathologic role these 
autoantibodies play. Therefore, the debate about the role of autoantibodies in the 
pathogenesis of MS is ongoing. 
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The hygiene hypothesis and its proposed effect on autoimmunity development may hold 
relevance for understanding the mechanisms behind MS disease course and development. 
Evidence to suggest MS may be alleviated through infection, and conversely exacerbated 
through lack of exposure to infection has been documented50, highlighting a potential 
association between immune system function and infection. Whether those who have less 
exposure to infectious agents are at reduced risk of developing MS is, however, yet to be 
ascertained51. Exposure to Epstein-Barr virus could be considered as a specific aspect of 
the hygiene hypothesis. 
2.1.4. Obesity 
Previous studies have provided evidence of an association between high BMI, and MS 
susceptibility52. Adipose tissue can influence immune system function through secretion 
of adipokines and cytokines, including leptin, which can influence T-cell activity53. This 
perspective suggests individuals with obesity maintain a low-grade chronic inflammatory 
state, culminating in increased susceptibility to autoimmune disorders alongside other 
adverse clinical outcomes54. 
2.1.5. Smoking 
Smoking has been shown to be a risk factor for MS development regardless of age at 
exposure, with the increased risk of MS abating a decade after smoking cessation55. The 
mechanism through which smoking influences MS risk is incompletely understood, but a 
number of theories have been proposed. One possible explanation relates to the cyanide 
present in inhaled tobacco, which has been shown in animal studies to induce selective 
demyelination56. Cyanide administered in smaller, regular doses, perhaps similar to the 
doses regular smokers would be exposed to, more successfully produced demyelinative 
lesions than when one large dose was administered. There is also evidence to suggest 
cigarette smoke has inflammatory properties such as increasing peripheral leukocyte 
counts, which could be instigating and exacerbating MS development57. Although several 
theories have been proposed, they have not been conclusively verified, and some have 
shown nicotine could have a potentially protective effect against the development of 
autoimmune diseases58. 
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2.2. TREATMENT OF MS 
For treatment naïve MS patients, there are four first line treatments recommended in 
Sweden: glatiramer acetate (GA), interferon (IFN)-β 1a, and, IFN-β 1b, and dimethyl 
fumarate (DMF). Corticosteroids are often also used in instances of acute MS relapse59. 
Second line treatments include fingolimod and natalizumab60. In addition to the 
recommended first line treatments, Rituximab is often prescribed off label, meaning there 
is limited information on the long term safety and efficacy of this treatment for MS 
patients61. When and how to make the transition from first line to second line treatment 
can be difficult, with no internationally recognised guidelines on when the decision 
should be taken and how it should be implemented62.  Immunomodulatory treatment 
alters the functioning of the immune system, which has the potential to provide 
improvements to MS patients through reduction in symptoms, and delays in disease 
progression for in particular RR patients.  
2.2.1. First Line Treatments 
GA, one of the first immunomodulators to be approved for use in RR MS patients, 
induces the expression of anti-inflammatory cytokines, which can suppress 
demyelination and reduce the possibility of relapse. IFN-β modulates antigen 
presentation, and can decrease T-cell production of IFN gamma. This treatment has the 
possibility to reduce the entry of T-cells into the CNS, thus reducing the probability of 
damage or injury to the CNS due to T-cell activity63. Patients treated with IFN-β 
commonly experience flu-like symptoms shortly after treatment is administered, which 
usually subside soon after64. Treatment with DMF appears to work through the effects of 
DMF on the nuclear factor (erythroid derived 2)-like2 (NRF2) pathway, altering NRF2’s 
immune regulatory properties, meaning DMF has the potential to act as a cytoprotecting 
agent65. 
2.2.2. Off label treatment with Rituximab 
Rituximab is becoming increasingly common as a treatment for MS. Rituximab is a B-
cell-depleting monoclonal antibody acting primarily against CD2066. The targeting of 
CD20, a phosphoprotein expressed on the surface of B-cells, results in B-cell lysis, and 
subsequently to B-cell peripheral depletion67. The effect of rituximab on B-cell depletion 
reduces inflammatory activity, and therefore has the ability to reduce relapse rates and 
subsequent CNS injury due to demyelination68. Although current evidence suggests 
rituximab is effective, and has discontinuation rates lower than is the case for other 
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DMD’s66, this treatment is not yet approved for the treatment of MS, and is therefore 
only used off label. This medication is currently approved for the treatment of certain 
autoimmune disorders, including rheumatoid arthritis, as well as certain types of cancers 
of the blood, including non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia69. 
2.2.3. Second Line Treatments 
Natalizumab is a monoclonal antibody, which suppresses the entry of leukocytes into the 
CNS63, 70. Phase 3 clinical trials have indicated that patients treated with natalizumab had 
reduced probability of sustained disability progression, and increased probability of 
remaining relapse free for 2 years. Treatment with Natalizumab, as is the case for all 
treatment, is not risk free. In particular, the risk of development of progressive multifocal 
leukencephalopathy (PML), a rare opportunistic infection of the oligodendrocytes and 
astrocytes, is increased in patients treated with Natalizumab. Although the risk is 
increased for patients using natalizumab, the probability of developing the disease 
remains very low for those in treatment71.  Fingolimod reduces  autoaggressive 
lymphocytes infiltration into the CNS63, and thus reduces autoimmune CNS damage . 
2.2.4. Effect of Treatment on Disease Progression 
Disease modifying drugs (DMD’s) such as the ones described are thought to aid in 
delaying the time until the onset of SP MS in patients initially diagnosed with RR MS72. 
The reasons behind why DMD’s are able to delay the onset of SP MS are thought to 
relate to their ability to reduce the inflammatory processes MS patients’ experience. This 
can in turn reduce the extent of CNS injury resulting from a dysfunctional autoimmune 
response, and delay the neurodegenerative process73. The progression of disability has 
also been shown to be reduced for patients treated with DMD’s, again providing evidence 
for a potential protective effect against CNS injury74. 
2.2.5. Treatment in Progressive Subtypes 
Most immunomodulatory treatments seem only to be effective in predominantly 
relapsing subtypes of MS75. Until recently, there were no approved treatments for PP MS, 
with all clinical trials showing no evidence of benefits for patients relative to placebos76. 
The reasons for the lack of effectiveness of conventional treatments for progressive 
subtypes is incompletely understood. One suggestion is that most conventional treatments 
target immune system abnormalities in the periphery, which may be only a minor aspect 
  18 
in the accumulation of damage to nerve tissue during the progressive phase. Effective 
treatment of the progressive stage may therefore require drugs targeting both peripheral 
and central immune dysfunction76. In March 2017, Ocrelizumab, a monoclonal antibody 
that targets and depletes CD20+ B-lymphocytes became the first treatment to be 
approved for PP MS77 after clinical trial evidence of disease activity reduction for PP MS 
patients treated with Ocrelizumab relative to placebo78. The reasons for its success in 
clinical trials for PP MS patients are incompletely understood, and has to some degree 
reignited the debate surrounding whether MS is primarily a T- or B-cell mediated 
disease79. 
2.2.6. Recent developments in MS treatment 
More recent developments in MS treatment include treatments such as Cladribine, which 
is believed to be beneficial for patients with highly active RR MS in particular80. 
Cladribine is a deoxyadenosine analogue which reduces the pro-inflammatory response 
through depleting lymphocytes80. Teriflunomide is another anti-inflammatory medication 
used in MS, in which the proliferation of rapidly dividing cells, including activated 
lymphocytes, is inhibited81. This inhibition is believed to reduce the extent of the 
inflammatory response, and thus reduce CNS injury and demyelination in MS patients. 
Alemtuzumab, a drug approved for patient use in 2013, is a relatively recent development 
and is currently primarily prescribed in instances where two or more drugs indicated for 
the treatment of MS have received an inadequate response from the patient82. 
Alemtuzumab depletes the supply of T- and B-cell lymphocytes through antibody-
dependent, and complement dependent cytolysis. Repopulation of lymphocytes usually 
begins weeks later. The therapeutic effects of Alemtuzumab are believed to relate to both 
lymphocyte depletion and repopulation. During repopulation the proportion of regulatory 
and memory T-cells increases, and the proportion of naïve T cells is decreased83. 
Proportions for B-cell subtypes is also altered, which is thought to affect the auto-
inflammatory response in MS patients. The fact that this treatment option results in 
prolonged lymphocytopenia means it is only generally considered after other treatments 
have been shown to be ineffective84, because this state of immunity leaves patients at 
increased susceptibility to opportunistic infections. 
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3. PROGNOSIS FOR MS PATIENTS 
It is known that life expectancy for MS patients is generally approximately 10 years 
shorter than life expectancy for the non-MS population, although there have been 
improvements for MS patients over recent years85. Alongside reductions in life 
expectancy, MS patients are at risk of comorbidity from other diseases, including mental 
health diagnoses such as depression and anxiety86. Hypertension and hyperlipidemia have 
also been reported as common comorbid diseases. Marrie & Horwitz87 discuss possible 
mechanisms which could result in the coexistence of MS and other disorders within the 
same individual. They discuss the possibility that increased utilization of health services 
could result in higher prevalence of certain diagnoses due to a form of surveillance bias in 
which there is more opportunity for individuals with MS to be given diagnoses relative to 
the non-MS population. Another possible pathway discussed by Marrie & Horwitz is that 
the risk factors for MS could be common to other diseases. For example, smoking and 
obesity, both believed to be risk factors for the development of MS, are also risk factors 
for many other diseases and disorders, including hypertension, and hyperlipidemia. 
Alongside common risk factors relating to lifestyle being a possible mechanism for 
comorbidity in MS patients, there is also evidence to suggest MS patients are at increased 
risk of developing other autoimmune disorders including asthma, and inflammatory 
bowel disease. The risk for other diseases such as bipolar disorder, and melanoma are 
also believed to be increased in MS patients88. MS patients have been reported to be more 
likely to have a family history of autoimmune disorders relative to the general population, 
providing evidence for a possible genetic susceptibility to other diseases relating to the 
immune system89. 
MS patients have also been shown to be at increased risk of hospitalization due to 
infection90. The reasons behind why MS patients are more likely to be admitted to 
hospital with infections could in part relate to surveillance bias due to MS patients having 
more regular contact with health services, providing increased opportunities for 
diagnosis, and subsequent hospitalization and treatment. Surveillance bias, however, is 
unlikely to be the only explanation for the increased risk, given that hospital admission 
indicates a relatively serious condition unlikely to be diagnosed by chance during 
scheduled visits. Infection-related mortality is also higher among MS patients85, 90, again 
providing evidence of a genuinely increased risk of infection rather than the association 
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being solely related to surveillance bias. The potential reasons for increased infection 
susceptibility in MS patients could relate to the effect of immunosuppressive treatments, 
which could inhibit an immune response to infectious agents84. In particular, MS patients 
on immunosuppressive therapies are at raised risk of opportunistic infections including 
multifocal leukoencephalopathy71, although even with a raised risk instances of such 
severe infections remain rare. 
3.1  DISEASE PROGRESSION IN MS PATIENTS 
The Expanded Disability Status Scale (EDSS) proposed in 1983 is the most commonly 
used tool to evaluate the severity of neurological impairment among MS patients91. In 
general patients show deterioration over time92. The scale considers eight functional 
parameters: bowel and bladder, brainstem, visual, pyramidal, cerebral, cerebellar, 
sensory, and ‘other’. One section of the scale focuses on functional parameters, and a 
second section focuses on degrees of mobility for patients. The score can range from 0 
(normal) to 8 (maximal impairment).  The measure should be considered ordinal, 
meaning differences between scale steps are not constant93. 
The types of disability found in MS patients can be variable depending on the individual. 
Fatigue is a particularly commonly reported disabling symptom94, although the reasons 
behind why MS patients report fatigue to a greater degree than the non-MS population 
are unclear. Bol et al. (2010)94 have investigated possible explanations behind the 
experience of fatigue reported by MS patients, and considered both a biomedical and a 
cognitive-behavioural explanation. The effect of fatigue on other aspects of health, 
including mental health, and physical activity can be substantial, highlighting the 
importance of studying whether the underlying cause of the fatigue is due to the 
biological processes involved in the disease (biomedical model) or the patients’ 
interpretation of their condition (cognitive-behavioural model). Bol et al. concluded that 
both biomedical and cognitive-behavioural factors were involved in the impact of fatigue 
on other aspects of health and disability, and suggest that the effect of biomedical 
processes on health are mediated by cognitive-behavioural processes and therefore an 
integrated approach to treatment should be taken. 
Pain is another common symptom of MS, which can contribute substantially to disability 
progression among patients95. Pain can be difficult to objectively measure, which has 
resulted in widely differing estimates of the extent to which MS patients experience pain 
  21 
relating to their disease. Higher levels of pain are a risk factor for lower levels of physical 
activity96, which can in turn have implications for the development of comorbid 
conditions such as obesity and diabetes, making pain an important symptom to measure. 
Neuropathic pain in particular is commonly seen among MS patients, and derives from 
lesions as a result of injury to the CNS97. Trigeminal neuralgia, resulting from damage to 
the trigeminal nerve which runs through the face, has been found to be common among 
MS patients, with symptoms of sudden shock-like pain to the side of the face the most 
typical presentation98. Trigeminal and non-trigeminal neuralgia are both types of 
neuropathic pain usually present due to nerve injury in MS patients. Spasticity, another 
common MS symptom, can limit joint mobility and decrease muscle flexibility, and 
ultimately induce pain99. 
Alongside progression in disability over time, some patients diagnosed with RR MS go 
on to develop SP MS. Scalfari et al (2014)100 found particular risk factors for entering the 
SP disease stage were disease duration, male sex, older age at MS diagnosis, and high 
rate of relapse. The authors stated that onset of SP is the most important determinant of 
long term prognosis, meaning the prevention of transition from RR to SP MS is of 
paramount importance, and highlights the strong association between disease stage, and 
disability progression. 
4. PREGNANCY OUTCOMES FOR MS PATIENTS 
There is little evidence to suggest women with MS are at increased risk of adverse 
pregnancy outcomes relative to women without MS101. The majority of past studies have 
shown no significant difference in the mean gestational age, or birth weight of babies 
born to MS mothers102. Pregnancy outcomes including rates of miscarriage and 
malformation also do not appear to be increased in MS patients relative to the general 
population103, 104.  
During particularly the late stages of pregnancy, the relapse rate for MS patients is 
typically reduced105. In the postpartum period, however, rates of relapse tend to increase 
to above normal rates for reasons which are incompletely understood105. There is limited 
information available on disease course and pregnancy outcomes for women with 
progressive subtypes of the disease. 
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4.1. PREGNANCY OUTCOMES AND EXPOSURE TO MS DISEASE 
MODIFYING DRUGS  
Pregnant women are usually excluded from clinical trials, so evidence of the effect of MS 
DMD’s on pregnancy outcomes is largely based on the results of observational studies, 
and is currently somewhat limited. Past research on the effect of interferon exposure on 
pregnancy outcomes has been conflicting. Some studies have found an increased risk of 
outcomes including spontaneous abortion and stillbirth among pregnant women exposed 
to interferon relative to the general population106, whereas others indicate no increased 
risk of adverse pregnancy outcomes107. Research undertaken as part of the DMF clinical 
development program has indicated no increased risk of foetal abnormalities or other 
adverse pregnancy outcomes relative to the general population when women are exposed 
to DMF during pregnancy108. There is also evidence to show the use of GA during 
pregnancy is likely to be safe, with no increased risk of congenital abnormalities found 
for infants prenatally exposed to GA relative to those with no prenatal exposure109.  
Prenatal exposure to second line treatments including natalizumab and fingolimod also 
appears to be safe110, 111, however small numbers recruited into past studies mean it is not 
possible to draw definitive conclusions. Studies into the area of MS treatment during 
pregnancy have proposed future research into identification and measurement of accurate 
biomarkers for disease activity and prognosis. This would prove helpful when decisions 
relating to whether or not to treat at different stages of pregnancy are being made112. 
Currently, the most common approach in Sweden is to cease all MS treatment during 
gestation in part due to the natural immune suppression which occurs during 
pregnancy113. The guidelines for MS DMD’s including interferon state treatment should 
be discontinued during pregnancy. Further research with populations of MS women are 
needed in order to gain insight into whether the advice of the guidelines is warranted. 
5. AIMS OF THE PRESENT STUDY 
Past research into prognosis and consequences of living with multiple sclerosis as 
described in the previous chapters provided the impetus for the current study. The study 
was separated into four main aims, each of which comprised a separate paper, which 
considered different stages of the life course for MS patients, and focused on different 
aspects of the disease and the implications for MS for patients. With topics covering 
issues relating to pregnancy, symptom management, and life expectancy, the study aimed 
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to cover the consequences of living with MS over the years from the time many 
individuals are diagnosed, up until the end of life.  
The specific aims of each study were: 
1. To consider to what extent MS patients were at increased risk of mortality at any 
given age relative to individuals without MS, and whether MS patients were at 
particularly elevated risk of death from a specific cause relative to those without 
MS. A secondary aim was to assess whether there were changes over time in 
terms of survival for MS patients, and how this compared to those without MS. 
Whether there had been changes in cause specific mortality over time for MS 
patients relative to non-MS comparators was also considered. 
 
2. To assess whether the hypothesised association between MS and pain was evident 
using pain medication use as a proxy. Whether MS patients were at particularly 
high risk of neuropathic pain, migraine, or musculoskeletal pain relative to non-
MS comparators was a secondary aim. 
 
3. To assess whether the DQB1*0302 genotype is associated with the risk of pain, 
and whether the risk is modified by the presence or absence of MS given the 
findings of previous studies.  
 
4. To investigate whether exposure to interferon-beta, a commonly used MS DMD, 
impacted on the birth measurements of infants prenatally exposed to the 
treatment, relative to those unexposed to any MS DMD’s. 
6. CONSEQUENCES OF MS THROUGH THE LIFE 
COURSE 
6.1. CHILDHOOD AND ADOLESCENCE 
Pediatric onset MS (POMS) is rare, with less than 1% of MS patients presenting with 
symptoms under the age of ten114. It has been observed that a higher proportion of POMS 
patients are diagnosed with the RR subtype of MS relative to the adult-onset MS 
population, with relapses appearing more frequently in RR MS POMS patients than 
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would be expected for those diagnosed with RR MS in adulthood115. POMS patients are 
increasingly recognised as having a more inflammatory disease course, which can have 
consequences for disease progression114, with this patient group appearing to reach 
disability at a younger age, and have a poorer long term prognosis than their adult-onset 
MS counterparts116. There have been no large placebo-controlled studies considering 
whether POMS responds to treatment in the same way as adult-onset MS, and no MS 
DMD’s are currently approved in POMS patients. DMD’s prescribed for the adult-onset 
population are currently also used in POMS patients, however it is plausible, given the 
more inflammatory disease course, that adult treatments may not be the ideal option for 
POMS patients.  
6.2. ADULTHOOD 
6.2.1. MS and Economic Activity 
The majority of MS patients are diagnosed in adulthood, with a mean age of diagnosis of 
approximately 35 years. One of the most commonly reported and difficult to manage 
symptoms among MS patients is fatigue, which can impact on capacity to work, and fully 
engage in daily activities117. Despite being one of the most common MS symptoms, 
fatigue remains a poorly understood research area, however several mechanisms for why 
this patient group experiences fatigue to a greater degree than the general population have 
been proposed118. These possible pathways have been broadly discussed in terms of 
primary, and secondary mechanisms. A compelling argument for a possible primary 
mechanism entails the effect of axonal loss, which can result in compensatory 
reorganisation, requiring increased brain activity from the patient relative to what would 
have been required had axonal loss not occurred. This can result in depletion of energy 
through elevated demand on functioning neural circuits119. Secondary mechanisms relate 
to the possible association of fatigue with disease burden, including increased risk of 
sleep disorders, depression, and disability among MS patients, outcomes which have 
been linked to fatigue118. In these instances, the comorbidity would likely be acting as a 
mediator between MS and fatigue. Many MS patients require adapted working 
environments in order to be economically active, including regular relaxation time and 
reduced working hours relative to the general population120. Pain, another commonly 
reported symptom of MS patients, has previously been associated with fatigue121. Pain 
can impact on quality of life, including through its impact on fatigue, in a number of 
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ways, including through interrupting sleep, and increasing the demands of physical 
mobility121. Experiences of pain also reduce the capacity for economic activity in MS 
patients, particularly if the work is physically demanding, and can be a leading cause of 
disability among this patient group122. The consequences of these experiences of MS 
symptoms on adult patients can ultimately reduce economic activity, which can impact 
on income, and other resources.  
6.2.2. MS and Parenting 
In addition to the impact of MS on economic activity, patients are commonly diagnosed 
at an age when parenting is becoming an important issue for many123. This has 
particularly strong implications for women, due to the issues surrounding treatment 
decisions during pregnancy, as has been previously discussed. Women comprise two 
thirds of MS patients, so the majority of those diagnosed will be affected by these issues 
if they wish to become parents. In addition to the previously mentioned issues relating to 
pregnancy, MS can impact on parenting itself124, particularly if the patient experiences a 
relapse, or has a progressive MS subtype which can mean symptoms are particularly 
pronounced. Past research has reported children whose parents have MS can feel a 
greater sense of burden, and felt a higher degree of responsibility relative to the children 
of healthy parents125, which can result in behavioural problems126. Some studies, 
however, have concluded that the effect of having a parent with MS on children can be 
positive. For example, having a parent with MS has been shown to be associated with 
pro-social behaviour in youth127, and with increased empathy in children128. Whilst there 
have been studies looking into parenting with an MS diagnosis, it remains an under-
researched area, meaning the long term impacts, both positive and negative, of parenting 
with MS on both the parent and child, remain incompletely understood and further 
research is warranted129.  
6.3. LATER ADULTHOOD, MS, AND DISEASE PROGRESSION 
Diagnosis after the age of fifty is considered to be rare130. Research into the area of how 
those with later onset MS are affected is an underreported research area131, however there 
are indications that those diagnosed later in life are at substantially increased risk of 
having a progressive subtype of MS relative to those diagnosed at a younger age130. 
Regardless of age at diagnosis, those aged 50 or over are at increased risk of living in the 
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progressive disease stages whether it be PP MS or SP MS, which has relevance for 
quality of life and daily activities for this age group. 
For those diagnosed before fifty, one of the main determinants of long term prognosis 
and disease burden as patients age is whether those initially diagnosed with RR MS 
transition to SP MS100, 132. Research into how this transition can be prevented is therefore 
of vital importance. Disease course is often unpredictable, and the underlying 
mechanisms behind why some RR MS patients progress to SP MS and others do not is 
incompletely understood133. The effect of MS DMD’s once the progressive phase has 
been reached is less clear than is the case for RR MS, highlighting the importance of 
preventing transition to SP MS since treatments cannot necessarily be depended on to 
alleviate symptoms to the same degree134.  
Current evidence indicates approximately a quarter of MS patients are mature adults over 
the age of 65, a number likely to rise as life expectancy improves135. Living with MS is 
known to reduce health related quality of life (HRQOL) in this age group, with influence 
on physical functioning, activities of daily life, and satisfaction with life all factors used 
in HRQOL measures that have been associated with MS. Past studies have argued that, 
whilst not a substitute for MS treatment, understanding the factors which reduce HRQOL 
among older adults with MS is of importance when trying to understand disease 
perception and how life is affected for this growing patient group135. 
6.4. END OF LIFE AND LIFE EXPECTANCY ISSUES 
Whilst past research has indicated a 7-14 year reduced life expectancy for MS patients 
relative to those without MS136, improved survival for MS patients over time has been 
observed, and MS survival is beginning to more closely reflect the survival rates seen 
amongst those without MS85. In addition to a shorter average life expectancy, years spent 
with a disability tends to be higher among MS patients relative to those without MS, and 
the compression of morbidity seen in the general population137 is reduced amongst MS 
patients who tend to live for a longer period of time with a disability over the life 
course138. Recent trends, however, seem to indicate reduced rates of progression from RR 
to SP MS due at least in part to the development of DMD’s72, with many patients living 
into old age without acquiring a progressive disease subtype133. The reduction in the 
conversion rate from RR to SP MS could be driving the improvements to the health and 
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wellbeing of MS patients reaching older age, and ultimately improving both the 
morbidity and mortality of the MS population over time139. 
7. DATA SOURCES FOR MS RESEARCH IN SWEDEN 
SWEDISH REGISTERS  
Public administration and health services maintain various electronic records, many of 
which can be accessed for research through the Swedish registers maintained by the 
National Board of Health and Welfare (Socialstyrelsen) and Statistics Sweden. All 
Swedish residents are provided with a unique personal identification number at birth or 
immigration, which allows for these registers to be linked140. The registers discussed in 
this chapter are relevant for the study of MS patients and were utilised for this thesis. 
7.1. THE TOTAL POPULATION REGISTER 
The total population register began in 1968 and has been maintained since then by 
Statistics Sweden (SSB)6. Information within the register contains inhabitants place of 
residence, civil status, sex, date of birth, date of death, and date of migration and has done 
so annually since 1968.  
7.2. THE NATIONAL PATIENT REGISTER (NPR) 
In Sweden, the National Patient Register (NPR) provides data on the diagnoses of 
Swedish residents, including diagnoses of MS. Data on inpatient visits has been available 
since 1964, however coverage was not universal until 1987141. Since 2001, data has also 
been available on outpatient visits142, with coverage improving over time. The register 
contains information on the International Classification of Disease (ICD) codes for 
primary diagnoses, alongside information on secondary diagnoses. Date of admission for 
the in- and out-patient registers, as well as discharge date for the inpatient registers are 
available. Procedure codes are also included in the register. Whilst coverage for these 
registers is high, the validity of the data varies depending on the diagnosis. This data is 
held by the Swedish National Board of Health and Welfare (NBHW), known in Swedish 
as Socialstyrelsen.  
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7.3. THE PRESCRIBED DRUGS REGISTER (PDR) 
Information on prescribed treatment can be found in the Prescribed Drugs Register 
(PDR). The PDR contains information on the drug prescribed using anatomical 
therapeutic classification (ATC) codes, on the date of prescription, dispensation, dosage, 
and brand name of the treatment. This register does not contain information on treatments 
administered in the hospital setting. Data from this register is available from July 2005. 
Only drugs collected at the pharmacy through a prescription are found in the PDR, which 
means treatments which are purchased over the counter, or which are never collected by 
the patient are not observable using this register. The data is held by NBHW. 
7.4. THE CAUSES OF DEATH REGISTER 
This register began in 1952, with universal coverage achieved in 1961. Since 1961, the 
register has been annually updated by NBHW, who hold this data143. The register 
contains information on primary and secondary causes of death using ICD codes, and 
date of death. The data is most reliable for those individuals who died in hospital in terms 
of both date and cause, with reliability decreasing with the length of time since the last 
hospital admission.   
7.5. THE MEDICAL BIRTH REGISTER (MEDISKA 
FODELSEREGISTRET- MFR) 
The Swedish medical birth register (MFR) provides information on all births in Sweden 
since 1973, and includes data on diagnoses of the mother and infant during and 
immediately after birth. Information is also collected on pre-existing diagnoses of the 
mother, smoking status of the mother, and mode of delivery144. Birth measurements are 
also recorded in this register. Data from the MFR can be linked to other register data 
including the MS register, and NPR using the unique personal identity number issued to 
all Swedish residents at birth or immigration. The data is held by NBHW  
7.6. THE SWEDISH MULTIPLE SCLEROSIS REGISTER (MSR) 
Since 1996, the Swedish MS quality register, a tool intended to monitor the level of care 
provided to MS patients in Sweden145, has provided more detailed information on patient 
disease status, treatments given, and measures of disability145. The register collects 
information on hospital administered treatments, and estimates of disability using the 
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expanded disability status scale (EDSS). Relapses are also recorded in this register. 
However, coverage is not complete and stands at roughly 80% of the prevalent MS 
population of Sweden145. Inclusion in this register requires the consent of the patient. As 
well as providing more in depth information on MS patients, this resource has a higher 
positive predictive value (PPV) of MS diagnoses than the patient registers145. This 
register is held at the Karolinska Institute. 
7.7. THE LONGITUDINAL INTEGRATED DATABASE FOR HEALTH 
INSURANCE AND LABOUR MARKET STUDIES (LISA) 
The longitudinal integrated database for health insurance and labour market studies 
(Longitudinell integrationsdatabas för sjukförsäkrings, LISA) contains information on 
education, income, and occupation146. LISA was officially initiated in 2003, however 
Statistics Sweden has been compiling the information included in the registers since 1990 
through information provided by the Swedish Social Insurance Agency 
(Försäkringskassan) which provides sick and disability leave information, the Swedish 
Public Employment Service (Arbetsförmedlingen) which gives information on 
employment status, and the Education Register (Utbildningsregistret) providing data on 
the educational attainment of residents.  
7.8. THE MIGRATION REGISTER 
Whilst this register was not used directly as an outcome or exposure in these MS studies, 
it was used to identify end of follow-up for emigrees. Information on date of 
immigration, and emigration are recorded and made available for study by the Swedish 
Migration Board6. 
OTHER DATA SOURCES 
7.9. EIMS, GEMS, AND IMSE 
The Epidemiological Investigation into MS (EIMS), Genes and Environment in MS 
(GEMS) and Immunomodulation and MS Epidemiology (IMSE) studies all began as 
case-control studies attempting to understand the role of environmental and genetic 
factors in MS diagnosis and progression147. In addition to collecting questionnaire data on 
lifestyle and exposures, blood samples were also collected from participants, which 
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allowed for genotyping and study into how genes could influence outcomes for a group 
of MS patients, and a group of matched comparators. 
8. METHODS 
8.1. STUDY DESIGN AND DATA 
8.1.1. Study 1 
Study 1 utilised a classic cohort design, in which all individuals identified as having had a 
diagnosis of MS either from the patient register, or through the MS register were 
identified and matched to ten randomly selected non-MS individuals who shared the 
same year of birth, sex, and county of residence at the time the MS patient was 
diagnosed. Data from the Total Population Register, Causes of Death Register, NPR, 
LISA, migration register, and MS register were utilised for this study. All matched 
comparators had to be alive at the point the MS patient was diagnosed. The matched 
cohort design uses differently exposed cohorts with shared (matched) characteristics (for 
example year of birth and sex), and follows up individuals over time to observe whether 
or not they experience the outcome. In this instance, the outcome was a record of 
mortality or, for cause specific analysis, a record of a particular cause of death according 
to the Causes of Death register. The study began in 1968 when the Total Population 
Register became available for the selection of controls. Whilst some MS diagnosed 
individuals were identified before 1968, it was not possible to match them to non-MS 
comparators until this point, so these earlier diagnosed patients were excluded from the 
study. Data was available until the end of 2012.  
8.1.2. Study 2 
This study made use of the EIMS, GEMS, and IMSE studies147-150. These studies were all 
designed as case-control studies, whereby MS patients were recruited during their visit to 
a neurologist. If the patient agreed to partake, up to two randomly selected individuals 
were taken from the Total Population Register matched by sex, year of birth, and place of 
residence at the point the MS patient was recruited into the study. For the purposes of 
study 2, intended as a study into how MS patients compare to others in terms of pain, all 
three studies were combined. Whilst originally designed as a case-control study in which 
questions on lifestyle and exposures were asked of participants, we used the data as a 
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cohort study which considered MS as an exposure. For all participants, Swedish register 
data was collected, and in addition to the EIMS, GEMS, and IMSE data, the PDR, 
Causes of Death Register, Migration Register, and LISA data were used. Whilst 
additional data is available in EIMS, GEMS, and IMSE, only register data was used for 
the purposes of this study. The research question looked at risk of pain amongst MS 
patients relative to non-MS comparators, and used prescriptions for pain relief as a proxy 
for a pain diagnosis as the outcome.  
8.1.3. Study 3 
The same data as was used for study 2 was used for this paper, along with additional 
information collected on genetics. For the collection of genetic data, participants were 
required to deposit a blood sample. For MS patients, this was undertaken when they 
visited their neurologist, however the non-MS comparators were required to visit their 
local health centre (vårdcentralen) for this. Again, the study was used as a cohort study, 
with exposure considered to be presence or absence of the DQB1*0302 allele. This allele 
has previously been indicated as associated with pain in patients undergoing inguinal 
hernia and lumbar disc herniation surgery, and has additionally been implicated in pain 
expression in murine studies. The outcome was the same as study 2, namely whether 
medications intended for pain relief were prescribed. MS was considered as a possible 
effect modifier. 
8.1.4. Study 4 
This study was part of an international collaboration, and included data from Sweden and 
Finland. All pregnancies to women with MS between 2005-2014 in Sweden were 
identified through the MS register or NPR, and between the same years in Finland, with 
MS identified using the Care Register for Health Care within Finland. Data on pregnancy 
outcomes was obtained from the MBR of the respective country. Birth measurements 
including birth weight in grams, birth height in cm, and head circumference in cm are 
recorded in the MFR, and exposure to treatment can be located in the Swedish and 
Finnish PDR’s, with additional information available in Sweden from the MS register. 
This was also a cohort study, in which women were categorised according to their 
exposure status, and followed up to ascertain birth measurements for their infants upon 
delivery.  
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8.2. STATISTICAL METHODS, OUTCOMES, AND EXPOSURES 
8.2.1. Study 1 
The primary analytical method for this study was Cox proportional hazard (PH) models. 
These models are a commonly used statistical method specifically for analysing time-to-
event data151. Individuals are followed up from the date they entered the study, in this 
instance the date the MS patient within the matched group was diagnosed, up until the 
date of death, date of migration, or the end of the study on 31st December 2012, 
whichever occurred first. The underlying time scale was attained age, allowing for an 
interpretation of the hazard ratio (HR) of mortality at any given age for MS patients 
relative to those without MS. An important assumption of these models is the 
proportional hazards assumption, which states that the ratio of the hazard for the event for 
the exposed and unexposed groups is the same over time. In this study, the proportional 
hazards assumption was tested through interacting the exposure with the underlying time 
scale, and a stratification variable added which separated time into year of entry if the 
assumption was violated. The addition of this variable accounted for differing 
proportional hazards across years. ICD codes were used to identify the primary and 
secondary causes of death. The specific ICD codes used for cause specific mortality 
outcomes are displayed in table 1. 
Table 1- ICD codes used to determine cause of death 
ICD codes  
  ICD 8 ICD 9 ICD 10 
CVD 39-45 39-45 I0-I9 
Respiratory 460-519 460-519 J0-J9 
Infection 001-139, 680-686 001-139, 680-686 A0-A9, B0-B9, L0 
Injury 800-999 800-999 V0-V9, W0-W9, X0-X9, Y0-Y9 
MS 340 340 G35 
In addition to considering overall and cause specific mortality, this study aimed to assess 
whether trends were present for both overall and cause specific deaths, and whether these 
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trends appeared to differ for MS patients relative to their matched comparators. In order 
to study this, we divided the time period between 1968-2012 into roughly 10 year periods 
(1968-1980, 1981-1990, 1991-2000, and 2001-2012). Each time period was analysed 
separately, with each individual included in the analysis for all the time periods to which 
they contributed study time. 
8.2.2. Study 2 
Cox PH models were also utilised for this study, which used 1st July 2005 or the date of 
MS diagnosis for the patient in the matched group as the date of entry, whichever 
occurred last. The reason for this is the PDR began on 1st July 2005, so outcomes of pain 
medication dispensation could not be identified before this date. The underlying time 
scale for this analysis was time since study entry, with follow-up ending on the date of 
death, date of pain medication prescription, or 31st December 2014, whichever occurred 
first. The outcome was a binary variable indicating whether or not pain medication had 
been dispensed during follow-up according to ATC codes recorded in the PDR. Different 
treatments can be prescribed depending on what the prescribing clinician believes the 
underlying cause of the pain to be, allowing for identification of specific pain types using 
pre-specified ATC codes. Pain was categorised into musculoskeletal pain, migraine, and 
neuropathic pain. The ATC codes used for each outcome are displayed in table 2 below. 
In addition to considering differences between MS patients and matched comparators, the 
study also compared the MS cohort members with each other in terms of risk of pain 
according to age and duration since MS diagnosis.   
Table 2- Codes used to identify pain outcomes 
ATC codes 
All pain 
medication 
N02A N02BE M03BB M03BC N02BA N03AX12 N03AX16 N02C 
N02BG10 N06AA09 N06AA10 
Migraine N02C 
Musculoskele
tal M03BB M03BC  
Neuropathic N03AX12 N03AX16 M02AB N06AA09 N06AA10 
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In addition to model construction, the waiting time distributions were also examined. 
These methods allow for a visual representation of time from study entry until first 
prescription, and can therefore provide a rough gauge of the proportion of the cohort who 
are likely to be prevalent users at study entry, and the proportion likely to be incident 
users152. This is particularly insightful when left truncation is present, as is the case for 
this study. 
8.2.3. Study 3 
Logistic regression models were used for this study, with genotype considered as the 
exposure, and pain medication utilisation again considered as the outcome, as a proxy for 
pain. Such models are commonly used in epidemiological studies with binary outcomes. 
In this instance, the outcome was the same as study 2, namely whether pain medication 
had been utilised according to the PDR during follow-up. Neuropathic pain was also 
considered as an outcome. The primary exposure of interest was genotype, and whether 
the individuals possessed the DQB1*0302 allele. Additionally, whether zygocity 
impacted on the risk of pain medication use was assessed, allowing for insight into 
whether exposure to a higher number of DQB1*0302 alleles impacted on the risk for 
pain. In order to assess whether the impact of the genotype differed according to MS 
status, the analysis was stratified according to whether or not the individual had MS, 
which can provide evidence of whether or not MS acts as an effect modifier for the 
DQB1*0302 genotype. The outcomes were general pain and neuropathic pain according 
to ATC code record, and were defined in the same way as study 2 (see table 3 all pain 
medication and neuropathic section for list of codes). 
8.2.4. Study 4 
This study considered pregnancy outcomes for women with MS according to their 
exposure to MS disease modifying drugs (DMD’s), primarily interferon-beta (IFN-beta). 
Generalised estimating equations (GEE) were utilised for this study, and birth 
measurements were considered as continuous variables. Exposure to IFN-beta was 
classified as a binary variable with a value equal to 1 if the pregnancy was identified as 
exposed. Pregnancies which were not exposed to any MS DMD’s were considered to be 
unexposed. A sensitivity analysis in which pregnancies exposed to any MS DMD’s were 
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compared to pregnancies unexposed to any MS DMD’s was also undertaken. Exposure 
was identified using ATC codes in the PDR, and through drug names in the MS register. 
In order to be considered as exposed, the woman needed to have collected a prescription 
from the pharmacy in the 6 months prior to LMP, under the assumption that the 
prescription is intended to last 3 months. Exposure therefore begins 3 months prior to 
LMP. This was the case for both Sweden and Finland. Within Sweden, it was also 
possible to identify whether treatments had been initiated during the exposure window as 
recorded in the MS register, in which case the pregnancy was also considered to be 
exposed. For identification within the MS register, the brand name of the treatment was 
needed. The ATC codes and treatment brand names are included in table 3. 
Table 3- ATC codes and drug names used to identify exposure to IFN-beta 
Treatments used to identify interferon exposure 
Brand 
names Avonex Plegidry Betaferon Extavia Rebif 
ATC 
codes L03AB07 L03AB08 L03AB13 
Treatments used to identify any MSDMD (same as used to identify interferon-
beta plus the codes listed below) 
Brand 
names 
Copaxone Gilenya IVIG Tecfidera Mitoxantrone Aubagio Lemtrada Tysabri 
Cladribine 
ATC 
codes 
J06BA02 L01AA01 L01BA01 L04AX03 L01BB04 L01DB07 L01XC04 
L03AX13 L04AA13 L04AA23 L04AA27 L04AA31 L04AX01 N07XX09 
 
 Birth weight in grams, height in cm’s and head circumference in cm’s as recorded in the 
MFR were used as separate outcomes. These models allow for consideration of the 
clustered nature of the data, in which siblings are clustered within the same mother. The 
GEE approach accounts for the fact individuals within the same cluster are more similar 
to each other than randomly selected individuals, and adjusts the variance accordingly.  
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SIBLING COMPARISON 
For this study, a differently exposed siblings family design approach was also undertaken 
as a sensitivity analysis. This method utilised cases where, within groups of siblings, at 
least one of the infants was prenatally exposed to treatment, and at least one infant was 
not pre-natally exposed to treatment. Sibling comparisons such as this can be considered 
as a quasi-experimental approach, in which traits other than the exposure of interest are 
randomised between siblings153. Confounding due to for example lifestyle or 
circumstance of the study subject cannot occur, because subjects cannot make decisions 
about exposure prior to their own birth. In these instances, all family constant 
confounders, including those which are unobserved, are controlled for. Confounders 
which are not family constant, for example maternal age and parity, need to be included 
in adjusted models when the differently exposed sibling design is used.  
9. RESULTS 
9.1. STUDY 1 
The study utilised data from 29617 MS patients matched to 296164 non-MS 
comparators. The study population characteristics are shown in table 4. 
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Table 4 Characteristics of MS and non-MS cohorts 
  With MS (%) Without MS (%) 
Total 29617 296164 
Sex 
  
Female 19658 (66.4) 196576 (66.4) 
Calendar period at study entry  
1968-1980 5197 (17.55) 51964 (17.55) 
1981-1990 5224 (17.64) 52240 (17.64) 
1991-2000 5777 (19.51) 57770 (19.51) 
2001-2012 13419 (45.31) 134190 (45.31) 
Age at MS diagnosis/entry  
<18 378 (1.3) 3757 (1.3) 
18-40 11684 (39.5) 116931 (39.5) 
41-64 14016 (47.3) 139970 (47.3) 
>=65 3539 (12.0) 35506 (12.0) 
Follow-up time  
 
<5 7806 (26.4) 62088 (21.0) 
5-10 years 8451 (28.5) 75918 (25.6) 
10-15 years 5065 (17.1) 48252 (16.3) 
>15 8295 (28.0) 109906 (37.1) 
Mean (SD) 12.1 (0.1) 14.6 (0.2) 
Educational level*  
 
Compulsory school or less 8199 (27.7) 78810 (26.6) 
Upper secondary 11719 (39.6) 117228 (39.6) 
Higher education 8061 (27.2) 84927 (28.7) 
No educational data available 1638 (5.5) 15199 (5.1) 
* In Sweden compulsory school is 9 years and upper secondary is 3 years. 
 
Within these cohorts, there were 9563 MS deaths, and 59295 non-MS deaths recorded in 
the Causes of Death register during the study period (1968-2012). The findings identified 
that at any given age, the HR for mortality for MS patients relative to those without MS 
was 2.92 (95% CI 2.86-2.99). The largest differences between the cohorts was seen for 
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respiratory diseases, for which the HR was 5.07 (95% CI 4.87-5.26). Table 5 provides 
details on overall and cause specific mortality. 
Table 5 Hazard ratios (HR) and 95% confidence intervals (CI) for mortality among MS 
patients compared with non-MS comparators 
 Event   
  MS  
Non-
MS  
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI) 
All deaths 
   
Total 9563 59295 2.72 (2.66-2.78) 2.92 (2.86-2.99) 
Sex 
    
      Male 3962 26365 2.57 (2.48-2.65) 2.75 (2.65-2.84) 
      Female 5601 32930 2.88 (2.80-2.97) 3.06 (2.97-3.15) 
 
Cause of death, underlying or contributing 
      Cardiovascular 4193 36396 2.22 (2.15-2.30) 2.06 (1.96-2.17) 
      Respiratory 3322 12284 4.89 (4.70-5.08) 5.07 (4.87-5.26) 
      Infections 440 2172 3.52 (3.89-3.15) 3.81 (3.40-4.20) 
      Injuries (inc. Suicides) 633 4842 2.06 (1.89-2.24) 1.72 (1.44-2.06) 
 
 
Cause of death underlying only 
      Cardiovascular 2593 26813 1.90 (1.82-1.98) 1.85 (1.74-1.97) 
      Respiratory 605 3900 3.03 (2.78-3.30) 3.08 (2.82-3.36) 
      Infections 135 727 3.42 (2.84-4.12) 3.76 (3.12-4.53) 
      Injuries (inc. Suicides) 280 2658 1.50 (1.32-1.70) 1.28 (0.94-1.75) 
*Adjusted for sex, year of entry, region and highest educational attainment, and stratified by year of 
entry in the model.  
**Underlying or contributing causes % do not add up to 100 because groups are not mutually 
exclusive  
(i.e. 1 individual may be in more than 1 group if they have more than 1 cause of death).  
The survival curves for the cohorts are shown in Figure 1. 
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Figure 1- Survival curves for MS and Non-MS cohorts 
 
 This study was able to provide strong evidence of improvements in survival over time 
for both the MS and non-MS cohorts. Importantly, the rate of improvement for MS 
patients was shown in this study to outpace survival improvements for the matched 
comparators. This was investigated through an interaction between time period, and 
exposure. Table 6 below shows the results of this interaction.   
Table 6 Interaction between time period and MS exposure 
  HR (95% CI) 
Non-MS Ref. 
MS 2.64 (2.55-2.73) 
Time period 
1968-1980 Ref. 
1981-1990 1.04 (1.00-1.08) 
1991-2000 0.91 (0.88-0.95) 
2001-2012 0.79 (0.76-0.82) 
Time period*MS-  
MS*1968-1980 Ref. 
MS*1981-1990 0.80 (0.53-1.20) 
MS*1991-2000 0.72 (0.48-1.07) 
MS*2001-2012 0.62 (0.42-0.92) 
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The interaction shows a larger magnitude movement from the reference time period 
(1968-1980) in terms of mortality for MS patients, relative to the entire study population. 
From this, it can be deduced that the MS patients must be improving at a faster rate than 
their matched comparators, who to some degree are pulling the HR closer to 1 when the 
entire study population is considered. 
The improvements to mortality can also be displayed through survival curves according 
to time period. Figure 2 shows that whilst there are improvements in survival for both 
cohorts, there is a clear narrowing of the gap as the survival for MS patients begins to 
more closely resemble the survival of their matched comparators. 
Figure 2- Survival curves by time period for the MS and non-MS cohorts 
  
In addition to overall survival improvements, there was a strong improvement in survival 
for all specific causes of death. Although there were substantial improvements to 
survival, the largest excess in mortality was still seen for respiratory and infectious 
diseases in the most recently studied time period (table 7). CVD was shown to be the 
leading cause of death for both the MS and non-MS cohorts. 
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Table 7- Cause specific mortality trends 
  MS events Non-MS events Adjusted HR* 
CVD    
1968-1980 483 1909 6.48 (5.50-7.63) 
1981-1990 984 6434 3.22 (2.86-3.63) 
1991-2000 1147 10498 2.30 (2.05-2.57) 
2001-2012 1579 17555 1.63 (1.48-1.79) 
Accidents    
1968-1980 33 191 2.04 (1.41-2.95) 
1981-1990 92 666 1.93 (1.56-2.41) 
1991-2000 170 1122 2.25 (1.92-2.65) 
2001-2012 257 2254 1.63 (1.43-1.86) 
Suicides    
1968-1980 25 70 4.06 (2.57-6.41) 
1981-1990 22 168 1.70 (1.09-2.66) 
1991-2000 32 197 2.14 (1.47-3.11) 
2001-2012 35 315 1.38 (0.97-1.96) 
Respiratory   
1968-1980 354 463 9.23 (8.03-10.61) 
1981-1990 707 1766 5.91 (5.41-6.46) 
1991-2000 919 3403 5.12 (4.44-5.90) 
2001-2012 1342 6652 2.98 (2.81-3.16) 
Infection    
1968-1980 8 24 4.02 (1.80-8.97) 
1981-1990 16 68 3.34 (1.93-5.77) 
1991-2000 66 352 2.80 (2.15-3.65) 
2001-2012 333 1721 2.82 (2.51-3.17) 
*Adjusted for sex, year of birth, place of residence, and highest educational attainment 
 
9.2. STUDY 2 
This study provided evidence for the hypothesised association between MS and pain risk. 
The study included 3877 MS patients matched to 4548 non-MS comparators. The cohort 
characteristics are summarised in table 8 below. 
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Table 8- Characteristics of the cohorts with and without MS 
  With MS, N (%) Without MS, N 
Overall 3877 (100) 4548 (100) 
Men 939 (24.2) 1080 (23.8) 
Women 2938 (75.8) 3468 (76.3) 
Age group at MS within matched group diagnosis 
<30 797 (20.6) 932 (20.5) 
30-39 1104 (28.5) 1293 (28.4) 
40-49 1086 (28.0) 1280 (28.1) 
50+ 890 (23.0) 1043 (22.9) 
Educational attainment 
Compulsory school or less 474 (12.2) 474 (10.4) 
Upper secondary 1755 (45.3) 2015 (44.3) 
Further/higher education 1645 (42.4) 2056 (45.2) 
No educational data available 3 (0.1) 3 (0.1) 
During the study period, 3082 MS patients, and 2285 non-MS comparators collected 
prescribed pain medication from the pharmacy according to the PDR.   
The study was able to provide evidence for the proposed association between MS and 
pain through confirming MS patients had an adjusted HR of 2.52 (95% CI 2.38-2.66) for 
pain medication dispensation relative to their non-MS comparators at any given point 
during the study period. Neuropathic pain was shown to be the primary reason for this 
increased pain risk, with an adjusted HR for neuropathic pain medication use of 5.73 
(95% CI 5.07-6.47). MS patients also had a significantly increased risk of migraine, 
however no differences were seen between the cohorts for musculoskeletal pain. Table 9 
shows these HR’s for adjusted and unadjusted models, along with stratification by sex. 
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Table 9- HRs for pain medication use among patients with MS and non-MS comparators 
 
The waiting time distributions for prescriptions also proved insightful. Their use was 
particularly helpful in this project due to left truncation because the PDR does not begin 
until July 2005. Waiting time distributions denote the proportion of newly recorded users 
of medication at any given point during the study period. A high, left skewed peak 
indicates a large proportion of users are most likely prevalent at the point the study 
begins. Figure 3 highlights the disparities in timing of prescription collection for MS 
patients relative to their non-MS comparators, with the left skewed peak at the beginning 
of the study time evident for MS patients, but not for the non-MS comparators. 
 
 
 
 
  MS Non-MS     
  Events (% of cohort) Events (% of cohort) Unadjusted HR Adjusted HR* 
All pain medication       
Overall 3082 (79.5) 2285 (59.2) 2.49 (2.36-2.63) 2.52 (2.38-2.66) 
Men 732 (78.0) 476 (44.1) 2.83 (2.52-3.18) 2.91 (2.58-3.27) 
Women 2350 (80.0) 1809 (52.2) 2.41 (2.26-2.56) 2.43 (2.28-2.58) 
Neuropathic pain treatment         
Overall 1326 (34.2) 325 (7.15) 5.66 (5.01-6.39) 5.73 (5.07-6.47) 
Men 290 (30.9) 48 (4.4) 8.20 (6.04-11.13) 8.48 (6.24-11.52) 
Women 1036 (35.3) 277 (8.0) 5.22 (4.57-5.97) 5.26 (4.61-6.01) 
Anti-migraine preparations       
Overall 250 (6.5) 247 (5.4) 1.18 (0.99-1.41) 1.20 (1.01-1.43) 
Men 21 (2.2) 24 (2.2) 1.00 (0.56-1.80) 1.04 (0.58-1.87) 
Women 229 (7.8) 223 (6.4) 1.20 (1.00-1.45) 1.23 (1.02-1.48) 
Musculoskeletal pain medication       
Overall 235 (6.1) 299 (6.6) 0.90 (0.76-1.07) 0.90 (0.76-1.06) 
Men 49 (5.2) 54 (5.0) 1.04 (0.71-1.53) 1.04 (0.70-1.53) 
Women 186 (6.3) 245 (7.1) 0.87 (0.72-1.05) 0.87 /0.71-1.05) 
*Adjusted for sex, region of residence, highest educational attainment, and age at study entry 
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Figure 3- Waiting time distributions for MS and non-MS cohorts 
 
In addition to considering whether MS patients were at increased risk of pain, and which 
pain subtypes appeared to be driving the difference, the study also considered how age 
and duration since MS diagnosis affected pain medication use. The findings showed that, 
among individuals who had been diagnosed with MS for the same amount of time, those 
who were younger were more likely to utilise pain medication (see table 10). The reasons 
for this are incompletely understood, but could relate to more active disease amongst 
younger patients. 
 
 
 
 
 
 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0
.0
1
0
.3
0
.6
0
.9
1
.2
1
.5
1
.8
2
.1
2
.4
2
.7 3
3
.3
3
.6
3
.9
4
.2
4
.5
4
.8
5
.1
5
.4
5
.7 6
6
.3
6
.6
6
.9
7
.2
7
.5
7
.8
8
.1
8
.4
8
.7 9
9
.3P
ro
p
o
rt
io
n
 o
f 
re
m
ai
n
in
g 
co
h
o
rt
 p
re
sc
ri
b
ed
 a
 p
ai
n
ki
lle
r
Study time in years
MS Non-MS
  45 
Table 10- Age at study exit adjusting for MS duration for those diagnosed on or after 
2005 (MS patients only) 
9.3. STUDY 3 
The same 3877 MS patients and 4548 non-MS comparators utilised for study 2 were also 
included in this study. Given that the sample and the outcome were the same, the same 
individuals were identified as having collected a prescription intended to treat pain during 
the study period (3082 MS patients, and 2285 non-MS comparators). Information on 
cohort characteristics can be seen in table 9 (unchanged from study 2). Among MS 
patients, 892 cohort members were identified as being heterozygous for the DQB1*0302 
  N Events All pain 
All pain 
   
<30 years at study exit 261 223 1.87 (1.57-2.22) 
30-39 years at study exit 433 344 1.40 (1.20-1.63) 
40-49 years at study exit 424 322 1.24 (1.07-1.45) 
50+ years at study exit 465 334 Ref. 
Neuropathic pain 
  
<30 years at study exit 153 53 1.37 (1.01-1.87) 
30-39 years at study exit 423 130 1.12 (0.89-1.41) 
40-49 years at study exit 438 138 1.14 (0.91-1.43) 
50+ years at study exit 569 168 Ref. 
Migraine  
  
<30 years at study exit 133 13 3.09 (1.56-6.12) 
30-39 years at study exit 384 26 1.98 (1.13-3.47) 
40-49 years at study exit 435 21 1.38 (0.76-2.49) 
50+ years at study exit 631 23 Ref. 
Musculoskeletal pain 
 
<30 years at study exit 129 5 1.01 (0.39-2.61) 
30-39 years at study exit 378 13 0.78 (0.41-1.50) 
40-49 years at study exit 447 24 1.19 (0.69-2.03) 
50+ years at study exit 629 30 Ref. 
*Adjusted for duration since MS diagnosis 
**Different N for ages at exit because an event (prescription) indicates age at exit- could be younger for all pain than e.g. migraine 
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allele, and 32 were identified as being homozygous for the allele. The corresponding 
numbers for non-MS comparators was 1092 and 79 respectively. 
The main finding of the study was the differential effect of allele possession on the risk of 
pain according to MS status. For MS patients, there was no association between carrying 
the DQB1*0302 SNP and pain, and there was no effect according to zygocity. The same 
was not true of the non-MS comparators, for which possession of the gene appeared to 
increase the risk of pain, particularly for women, and it appeared those homozygous for 
DQB1*0302 carried the highest risk of pain medication use. Table 11 shows the results 
when considering the effect of the possession of at least one DQB1*0302 allele, and table 
12 shows the results for the zygosity analysis. 
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Table 11- Odds ratios according to presence or absence of the allele 
  PPM Neuropathic PM 
Overall   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.09 (0.98-1.21) 1.07 (0.95-1.22) 
Men   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.13 (0.92-1.40) 1.19 (0.90-1.55) 
Women   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.07 (0.95-1.21) 1.04 (0.90-1.20) 
MS   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.02 (0.85-1.23) 1.14 (0.97-1.34) 
MS men   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.06 (0.73-1.54) 1.09 (0.78-1.51) 
MS women  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 0.99 (0.80-1.24) 1.14 (0.94-1.37) 
Non-MS   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.18 (1.03-1.35) 1.19 (0.93-1.54) 
Non-MS men  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.12 (0.83-1.49) 1.25 (0.63-2.46) 
Non-MS women  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ or +/+ 1.21 (1.03-1.41) 1.20 (0.91-1.59) 
*Adjusted for PCA's, sex, year of birth, and region of residence, and highest educational attainment 
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Table 12- Odds ratios according to number of alleles possessed 
  PPM Neuropathic PM 
Overall   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.08 (0.97-1.21) 1.09 (0.95-1.23) 
DQB1*0302 +/+ 1.17 (0.78-1.75) 0.87 (0.53-1.45) 
Men   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.16 (0.93-1.44) 1.22 (0.93-1.61) 
DQB1*0302 +/+ 0.82 (0.41-1.67) 0.69 (0.24-2.04) 
Women   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.06 (0.93-1.20) 1.05 (0.90-1.21) 
DQB1*0302 +/+ 1.36 (0.83-2.25) 0.94 (0.53-1.68) 
MS   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.05 (0.86-1.27) 1.14 (0.97-1.34) 
DQB1*0302 +/+ 0.60 (0.28-1.31) 1.18 (0.56-2.50) 
MS men   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.12 (0.76-1.64) 1.10 (0.78-1.54) 
DQB1*0302 +/+ 0.44 (0.12-1.59) 0.88 (0.22-3.52) 
MS women  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.01 (0.81-1.26) 1.13 (0.94-1.36) 
DQB1*0302 +/+ 0.67 (0.25-1.79) 1.34 (0.54-3.31) 
Non-MS   
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.14 (0.99-1.31) 1.17 (0.90-1.53) 
DQB1*0302 +/+ 1.97 (1.22-3.18) 1.49 (0.69-3.22) 
Non-MS men  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.09 (0.81-1.48) 1.23 (0.61-2.48) 
DQB1*0302 +/+ 1.41 (0.59-3.39) 1.39 (0.17-11.41) 
Non-MS women  
DQB1*0302 -/- Ref. Ref. 
DQB1*0302 -/+ 1.16 (0.99-1.36) 1.17 (0.88-1.56) 
DQB1*0302 +/+ 2.26 (1.25-4.06) 1.62 (0.70-3.71) 
*Adjusted for PCA's, sex, year of birth, and region of residence, and highest educational attainment 
 
An interesting aspect of the study was its reflection of the results of past murine models, 
which indicated possession of the genotype led to increased pain-like behaviour among 
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rats when considering peripheral nerve injury, however the same results were not found 
when considering spinal cord injury, which more closely mimics the injury that 
demyelination causes among MS patients. The fact that MS patients may be at increased 
risk of CNS rather than peripheral nerve injury could partly account for the lack of 
significance among MS patients when considering an association between the 
DQB1*0302 allele and pain medication use.  
9.4. STUDY 4 
The study made use of 1246 pregnancies in Sweden and 563 pregnancies in Finland for 
which data was available from the corresponding country’s MFR on birth weight, height 
and head circumference. Within Sweden, 411 pregnancies were identified as exposed, 
and in Finland 232 pregnancies were identified as exposed to IFN-beta. Details of the 
pregnancy cohort characteristics are shown in table 13 below. The unexposed group 
consisted of pregnancies unexposed to any MS DMD’s. 
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Table 13- Cohort characteristics 
  Sweden       
 
All 
 
Differently exposed siblings 
  Exposed Unexposed Exposed Unexposed 
Number of pregnancies 411 835 50 51 
Infant Sex  
   
Male (%) 207 (50.4) 441 (52.8) 24 (48.0) 26 (51.0) 
Female (%) 204 (49.6) 394 (47.2) 25 (52.0) 25 (49.0) 
Mean (SE) maternal age, years 31.3 (0.2) 32.3 (0.2) 31.0 (0.6) 30.9 (0.5) 
Maternal education 
   
Compulsory school or less (%) 20 (4.9) 56 (6.7) 2 (4.0) 2 (3.9) 
Upper secondary (%) 113 (27.5) 242 (30.0) 15 (30.0) 17 (33.3) 
Higher education (%) 277 (67.4) 534 (64.0) 33 (66.0) 32 (62.8) 
Missing data (%) 1 (0.2) 3 (0.4) 0 (0) 0 (0) 
Smoking status 
   
Smoker (%) 18 (4.4) 54 (6.5) 45 (90.0) 47 (92.2) 
Nonsmoker (%) 378 (92.0) 740 (88.6) 3 (6.0) 0 (0) 
Not known (%) 15 (3.7) 41 (4.9) 2 (4.0) 4 (7.8) 
  Finland       
 
All 
 
Differently exposed siblings 
  Exposed Unexposed Exposed Unexposed 
Number of pregnancies 232 331 41 42 
Infant Sex  
   
Male  117 (50.4) 171 (51.7) 18 (43.9) 18 (43.9) 
Female  115 (49.6) 160 (48.3) 23 (56.1) 24 (57.1) 
Mean (SE) maternal age, years 30.0 (4.2) 30.6 (4.5) 30.0 (4.2) 30.6 (4.5) 
Maternal education Not available Not available Not available Not available 
Smoking status 
   
Smoker (%) 33 (14.2) 49 (14.8) 2 (4.9) 3 (7.1) 
Nonsmoker (%) 195 (84.1) 277 (83.7) 39 (95.1) 39 (92.9) 
Not known (%) 4 (1.7) 5 (1.5) 0 (0) 0 (0) 
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Mean measurements for gestational age, and birth weight, height, and head 
circumference were similar across country and exposure status. Details are shown in table 
14 below. 
Table 14- Mean measurements for birth outcomes  
 
All 
 
Differently exposed siblings 
  Exposed Unexposed Exposed Unexposed 
  Sweden       
Number of pregnancies 411 835 50 51 
Mean (SE) Gestational age,  weeks,  39.7 (0.1) 39.5 (0.1) 40.0 (0.2) 39.2 (0.3) 
Mean (SE) Birth weight, grams 3465.9 (27.7) 3414.8 (19.4) 3475.5 (66.3) 3346.6 (81.7) 
Mean (SE) Birth height,  cm's 50.1 (0.1) 50.0 (0.1) 50.3 (0.4) 49.7 (0.4) 
Mean (SE) Head circumference, cm 35.0 (0.1) 35.0 (0.1) 35.0 (0.2) 34.7 (0.3) 
  Finland       
Number of pregnancies 232 331 41 42 
Mean (SE) Gestational age,  weeks,  39.4 (2.4) 39.5 (1.9) 39.5 (2.9) 40.0 (1.2) 
Mean (SE) Birth weight, grams 3357.5 (628.3) 3410.4 (541.0) 3306.6 (649.2) 3508.4 (441.7) 
Mean (SE) Birth height,  cm's 49.5 (3.1) 49.6 (2.5) 49.2 (3.8) 49.9 (1.9) 
Mean (SE) Head circumference, cm 34.5 (2.2) 34.8 (1.7) 34.4 (2.6) 35.0 (1.4) 
The findings of the GEE’s showed there were no significant differences in terms of birth 
measurements for infants prenatally exposed to IFN-beta relative to those unexposed. 
Table 15 shows the adjusted beta estimates for the mean birth measurements for birth 
weight, height, and head circumference for Sweden and Finland. Gestational age, sex of 
the newborn, smoking status of the mother, and maternal age at LMP are included as 
covariates. Results are displayed overall, and for differently exposed siblings. 
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Table 15- Adjusted GEEs for birth measurements 
  Adjusted*           
  Weight P-value Height P-value Head circumference P-value 
Sweden       
Overall  27.8 (20.1) 0.34 0.01 (0.1) 0.95 0.14 (0.1) 0.13 
Differently exposed siblings  -21.6 (77.1) 0.78  -0.10 (0.4) 0.78  -0.05 (0.3) 0.85 
Finland             
Overall  -50.3 (45.1) 0.27 -0.02 (0.2) 0.92 -0.21 (0.2) 0.15 
Differently exposed siblings -83.6 (79.8) 0.30 0.07 (0.4) 0.85 -0.008 (0.3) 0.98 
*Adjusted for gestational age, sex of the newborn, smoking status of the mother, and maternal age at LMP 
 
An additional sensitivity analysis which used an exposure window beginning at LMP up 
until the end of pregnancy was undertaken which showed no significant differences in 
birth measurements between those exposed to IFN-beta, and those unexposed to any MS 
DMD’s during the same time frame. 
A mixed effects model in which the intercept was allowed to vary according to maternal 
ID highlighted that a large proportion of the variance is derived from differences within 
sibling clusters, implying siblings are not homogenous for their birth measurements. The 
adjusted beta again shows the effect of exposure to IFN-beta relative to those unexposed 
to any MS DMD’s. Table 16 shows the results of the mixed effects models. The 
intraclass correlations demonstrated that overall, 46.4% of the variance for birth weight 
was explained by differences between rather than within clusters, with the corresponding 
numbers being 31.9% and 36.8% for birth height and head circumference respectively. 
For differently exposed siblings, power was greatly reduced, making it difficult to draw 
conclusions. It suggests the effect of clustering is not radically reducing the variance, 
because observations within the same cluster are not necessarily very similar. 
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Table 16- Mixed effects model with random intercept for maternal ID 
  Adjusted Beta (SE)* P-value Intraclass correlation (% (95% CI)) 
Overall 
   
Weight 27.5 (27.1) 0.310 46.4 (37.4-55.8) 
Height 0.001 (0.1) 0.994 31.9 (22.9-42.4) 
Head circumference 0.12 (0.1) 0.178 36.8 (27.5-47.2) 
Differently exposed siblings 
 
Weight  -24.0 (72.4) 0.740 31.3 (10.8-63.1) 
Height  -0.15 (0.06) 0.644 55.0 (33.9-74.5) 
Head circumference  -0.11 (0.26) 0.667 18.9 (3.8-58.0) 
*Adjusted for gestational age, sex of the newborn, smoking status of the mother, and maternal age at LMP 
The lack of effect of prenatal exposure to IFN-beta could be attributed to its 
pharmacokinetic qualities. Maternal and foetal blood is separated by the placental barrier, 
which is semi-permeable. In order for substances to pass from maternal to foetal blood, it 
must have a low molecular weight (between 600 and 800 Dalton154). The possibility that 
IFN-beta could permeate into foetal blood is therefore unlikely, because it is classified as 
a polypeptide with a molecular weight of 22kDa for IFN-beta 1a and 18.5kDA for IFN-
beta 1b155, which is too large to permeate the placental barrier. This demonstrates that the 
lack of effect of IFN-beta on birth measurements is biologically plausible. 
10. METHODOLOGICAL CONSIDERATIONS 
Caveats to each of the included studies should be considered. Limitations to the outcome, 
exposure, study design and analytic method can all influence results, so should be 
considered when drawing conclusions.  
10.1. STUDY 1 
Within the Causes of Death Register, it is known that the most accurate records of death 
in terms of both date and cause are for those who died in hospital. For those who did not, 
the longer ago the last hospital visit, the less accurate the death record tends to be143. In 
addition, the definition of underlying cause or causes of death is a complex process, and 
can be subjective. Clinicians are required to separate out conditions which contributed to 
the death from any other existing conditions the individual may have had which did not 
contribute to death. In addition, the conditions which directly lead to death should be 
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separated from those which contributed to the outcome, but did not directly lead to it (e.g. 
for a suicide relating to depression, the method used should be listed as the primary cause 
of death, with depression listed as a contributory cause). The quality of the entire death 
register has not been checked beyond the year 1995156. More recent validation of the data 
would therefore be beneficial. 
10.2. STUDY 2 
The main limitation with study 2 is the use of pain medication utilization as a proxy for 
experiencing pain. Some medications, such as pregabalin and gabapentin are also used as 
anti-epileptic medications, and amitriptyline and nortriptyline can be used to treat 
depression. For this reason, for study 2 a sensitivity analysis was conducted which 
excluded individuals identified as having had a diagnosis of epilepsy or depression in 
order to ensure consistency of results. However, if treatments are prescribed for a 
condition other than pain, this will detract from the specificity of the outcome. 
Conversely, it is not possible to identify those with pain who do not dispense medication 
at the pharmacy, which impacts on the sensitivity of the outcome. Another issue with this 
paper is the left truncation due to the PDR beginning in July 2005. It is not possible to 
identify the outcome before this date, meaning some individuals will have been living 
with MS for many years before study entry. It was therefore not possible to consider only 
incident users of pain medication, which would have provided stronger evidence of 
whether being exposed to MS results in higher rates of pain medication utilization. The 
waiting time distributions aided in giving some insight into prevalent users, and therefore 
could be considered a rough gauge for the proportion of each cohort using pain 
medication prior to the beginning of the study, however it is not possible to entirely 
separate prevalent from incident users.  
10.3. STUDY 3 
The outcome for this study was the same as study 2, so the same limitations to the 
outcome apply. In addition, another important consideration for this study is the issue of 
pleiotropy, which has implications for all genetic studies. Pleiotrophy is the process by 
which one gene influences two or more traits which may be seemingly unrelated157, 
which can make distinguishing between a direct biological effect, and a mediating effect 
difficult. In addition, complex traits such as experiences and perceptions of pain tend not 
  55 
to be the result of the characteristics of one particular SNP, rather it is likely they are the 
result of many genes spread throughout the genome158. This means that isolating one 
SNP for study could be limiting, because it may be the interaction of many SNPs that is 
ultimately affecting the phenotype. By studying one SNP, it is not possible to gain insight 
into whether the SNP itself, or other genotypes which tend to occur together with 
DQB1*0302 are the primary influencers of pain phenotype, or whether there is an 
interaction effect. 
10.4. STUDY 4 
 For study 4, only infants for which a birth weight, height, and head circumference was 
present were included. All three measurements needed to be available in order to ensure 
the same infants were being studied throughout. The limitation to this is that bias can be 
introduced if missingness is differential by exposure status. Within the Swedish data, 
25% of the unexposed and 17% of the exposed pregnancies had one or more missing 
birth measurement resulting in exclusion. The distribution of missingness cannot, 
however, give an indication as to whether missingness is differential, and bias can still be 
present even if the proportion missing is the same across two cohorts. In addition, register 
data is collected for administrative rather than research purposes, meaning there are a 
limited number of variables available. Therefore, it was not possible to adjust for 
potential variables of interest such as diet and physical activity, which could be 
associated (either directly or indirectly) to the decision to continue treatment during 
pregnancy, and to birth measurements.  
Methodological aspects of the differently exposed sibling design should also be 
discussed. There are three principle assumptions which should be upheld in order for the 
method to provide results which are generalizable and accurate. The first is exposure, 
outcome and other covariates must be accurately measured. This is because within-
cluster estimates are more severely influenced by non-shared confounders than 
conventional estimates which assume independence between observations159. The second 
assumption is non-contagion, in which the outcome or exposure of one sibling should not 
have the ability to affect the outcome or exposure of another sibling160, 161. This would 
mean the birth measurements of one sibling should not have the potential to influence the 
exposure status of another sibling. The third assumption is that differently exposed 
siblings are reflective of the general population160, meaning differently exposed siblings 
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should not differ in some fundamental way and should be representative of all infants153, 
including singletons, and those who are not differently exposed but are part of a sibling 
group. 
These assumptions should be considered and their plausibility assessed in order to avoid 
inaccurate interpretation of results. With regards to accurate recording of the exposure 
and other covariates, it seems probable any variations in such accuracy is likely to be at 
random, and should not majorly bias our results. The other two assumptions may prove 
more problematic, however. The decision to either continue with or cease treatment for 
one pregnancy could reasonably sway the decision made in future pregnancies. For 
example, if an infant is born with a complication (for example abnormal birth 
measurements, the outcome in this study) and the mother continued treatment during 
pregnancy, it may result in increased likelihood she decides against treatment during a 
later pregnancy. This mechanism could work in a number of ways, and a healthy birth for 
an exposed infant may also reassure the mother treatment is safe, and result in her 
decision to use it in future pregnancies, meaning her offspring are not differently 
exposed. This issue leads on to the possible violation of the third assumption, which is 
that differently exposed siblings are reflective of the general population. This may well 
not be the case, and mothers who do have differently exposed offspring may make 
treatment decisions for a variety of reasons, and ultimately the differently exposed sibling 
population may be fairly particular. This would reduce the external validity of the results. 
11. ETHICAL CONSIDERATIONS 
This chapter will consider the ethical implications of register data use and particular 
themes relevant to each paper. These considerations will be discussed through the lens of 
each of the four sections of principlism162.  
 The four principles included in the idea of principlism are doing good, avoiding harm, 
autonomy and justice. They were compiled in response to the syphilis study undertaken 
in Alabama from 1932-1972163. This study used African American subjects known to 
their clinicians to have syphilis, but were left unaware of their diagnosis, had readily 
available treatments withheld from them, and were subjected to what they believed were 
treatments, which were in reality research measurements.   
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 Investigating whether MS patients are at increased risk of particular outcomes, including 
death, could correspond with the first principle of doing good, because areas where 
improvements could be made can be highlighted. An alternative perspective is the idea 
that distress may be caused were patients made aware of the findings of these studies, 
perhaps in particular the increased risk of death. The ethical standing of this paper based 
on this principle would therefore depend on the cost-benefit relationship of improvements 
measured against harm caused by potential distress. In my view, the potential good which 
could come from the papers outweighs the risk of harm through potential patient distress, 
but means any reporting of the results particularly to patient groups should be handled 
with care. 
The second principle on avoiding harm is relatively easy to address in relation to register 
based studies. The life events of patients and other subjects are not affected by inclusion 
in such studies, and in fact for most register based studies (including the mortality and 
pregnancy outcome papers in this thesis), individuals are not aware they are part of a 
study. For papers 2 and 3 in which subjects were enrolled, harm is avoided if any medical 
procedures are carried out by trained medical professionals, as indeed they were. 
Additionally, harm in the form of leaked personal data is safeguarded by ensuring all data 
is kept on a secure server, and is not accessed outside the university setting 
For the studies included in this thesis, the most contentious principle is perhaps that of 
autonomy. Emphasis has been placed on the importance of autonomy and informed 
consent when using human subjects in research since the Nuremburg trials which 
occurred after the close of World War II, and came in response to experimentation 
undertaken without individual consent in concentration camps164. Informed consent is not 
gained for subjects for two out of the four studies which are entirely constructed using 
register data, which means the issue of autonomy and informed consent should be 
discussed. The fact that informed consent is not gained could be mitigated if real benefit 
can be gleaned from these studies. Therefore, the ethical standing of these papers could 
depend on the extent to which they prove beneficial to patients in the future. 
 The final principle is justice, which attempts to ensure that vulnerable groups are not 
unfairly subjected to scientific scrutiny without the potential for real benefits within their 
group being possible, or the benefits of the findings only being present in other groups165. 
With regard to this thesis, all studies consider MS patients, and are designed with 
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potential benefits for MS patients in mind. It seems unlikely that the possible health 
benefits which could come from the papers in this thesis would only be present in other 
groups, therefore it could be argued that the principle of justice is upheld in this thesis. 
A final ethical consideration which is relevant for this thesis outside the framework of 
principlism is that of conflict of interest, and the influence pharmaceutical companies 
may have over the papers166. For all papers, the funding sources and conflict of interest 
has been explicitly described and addressed. Furthermore, the pharmaceutical companies 
were limited in the extent to which they were allowed to influence the content and 
distribution of these studies. Whilst conflict of interest is clearly described in each paper, 
it does not entirely remove the implications and is worth contemplating when considering 
the ethical implications of the thesis.  
12. CONCLUSIONS 
MS is one of the most common non-traumatic causes of disability among young adults in 
many countries, yet much remains unclear about the consequences of living with the 
disease. The papers which are included in this thesis aim to add to the evidence base on 
the prognosis for this group in terms of their mortality, their experience of pain, and 
pregnancy outcomes which considers the effect of treatments. These studies consider 
different aspects of the disease, and cover topics ranging from those of concern at the 
mean age of diagnosis, namely how pregnancy can be affected by treatment, up until the 
end of life and how life expectancy can be affected by the presence of MS.  
Alongside overarching conclusions on consequences of living with MS for patients in 
Sweden, the thesis also reached more specific conclusions particular to the aims of each 
constituent paper. Survival time was shown to be reduced among MS patients, however 
major improvements over the past 40 years were identified. These improvements were 
evident for cause specific mortality, as well as overall mortality, and suggest the mortality 
trends of MS patients are beginning to more closely resemble those seen in the general 
population. The hypothesised increased risk of pain for MS patients was found to be 
evident using our data, with neuropathic pain in particular driving the increased risk of 
pain for MS patients. The expression of pain according to DQB1*0302 allele possession 
was found to be differential according to MS status, a finding hypothesised due to 
previous associations reported from murine studies. These studies highlighted CNS pain 
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was differentially influenced by this gene when compared to peripheral pain. Finally, the 
thesis concluded that exposure to interferon-beta during pregnancy did not seem to be 
associated with intrauterine growth. This finding is in line with the majority of past 
studies into the effect of pre-natal interferon-beta exposure on birth outcomes including 
birth measurements, which have shown null findings when comparing outcomes for those 
pre-natally exposed to treatment relative to those pre-natally unexposed. 
13. FUTURE PERSPECTIVES 
This thesis has attempted to gain a deeper understanding of the consequences of living 
with MS for a wide group of MS patients. Whilst the project has provided evidence for 
particular processes and associations, further work into particular areas would benefit the 
field of MS research. This could give further insight into how patients are affected both at 
specific times during their life, for example during pregnancy, and overall, providing 
information on issues such as symptom experiences and life expectancy. 
 The extent to which life expectancy is affected by diagnosis with MS has comprised part 
of this project, however whether this differs according to various factors including EDSS 
score, age at diagnosis, or disease course (i.e. whether the patient is RR, SP, PP, PR) 
would provide valuable insight into how more specific groups of MS patients are 
affected. Additionally, a clear trend was observed in this study which highlighted 
substantial improvements to survival for MS patients. Whether the gap between those 
with and without MS continues to narrow in the future would be informative, and help 
monitor how survival in these patients is progressing. 
The experience of pain was here identified using the PDR, allowing for an objective 
approach rather than being dependent on recall bias. Whilst there are advantages to this, 
there are drawbacks, such as lacking information on more specifically how quality of life 
and daily physical and mental functioning are affected. Data which specifically asks 
participants about pain, and how they are affected could be insightful when for example 
considering how to retain MS patients in the work force, or how best to adapt to their 
needs when prescribing certain treatments or physical therapies. Open ended, or 
qualitative studies, may add more nuance and allow for a more personalised insight into 
how patients are affected by this particular symptom. 
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The effect of genotype on disease course and various phenotypes such as pain is a rapidly 
growing area of interest. This thesis was only able to examine one previously identified 
single nucleotide polymorphism (SNP) of interest, with many others still to be 
investigated. The interaction between commonly occurring groups of alleles and pain 
would therefore be of interest. In addition, our study showed no increased risk of pain 
amongst MS patients with the DQB1*0302 genotype. Whether there are any particular 
genotypes which do increase the risk of pain amongst MS patients, in particular those 
found on the HLA complex, would therefore be of interest.  
Whether or not it is safe to continue with treatment during pregnancy is a difficult to 
study area. The study included in this project indicated there were no implications for 
birth measurements when women were exposed to IFN-beta during pregnancy. 
Guidelines tend to act on the side of caution, and will generally state treatments should 
cease during pregnancy, which could be problematic if the mother experiences symptoms 
and would ideally be able to continue with treatments. Observational studies such as this 
one for the other most commonly used MS DMD’s would go some way for providing 
specific guidelines for different MS DMD’s, and which treatments would be safest if a 
woman wishes to continue with treatment after conception.  
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